Viral hepatitis in alcohol-dependent inpatients: prevalence, risk factors, and treatment uptake

Standard

Viral hepatitis in alcohol-dependent inpatients: prevalence, risk factors, and treatment uptake. / Schmidt, Christiane Sybille; Schön, Daniela; Schulte, Bernd; Lüth, Stefan; Polywka, Susanne; Reimer, Jens.

in: J ADDICT MED, Jahrgang 7, Nr. 6, 2013, S. 417-21.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

APA

Vancouver

Bibtex

@article{b1689a862c9a4a68bae3be01d898bd31,
title = "Viral hepatitis in alcohol-dependent inpatients: prevalence, risk factors, and treatment uptake",
abstract = "OBJECTIVES: Most epidemiological literature on the prevalence of viral hepatitis in alcohol-dependent patients is based on older data. This study aimed to provide current estimates and an assessment of risk factors. We further investigated whether the initiation of antiviral hepatitis C virus (HCV) treatment is feasible after detoxification.METHODS: We assessed serological markers for hepatitis B virus (HBV) and HCV infection and liver enzyme levels (alanine aminotransferase, aspartate aminotransferase, γ-glutamyltransferase) in a sample of 463 inpatients in a tertiary care hospital, fulfilling International Classification of Diseases, Tenth Revision criteria for alcohol dependence. A subsample of 141 patients was interviewed on addiction history and risk factors for HCV acquisition. All patients with an indication for antiviral treatment were followed up.RESULTS: Compared with that in the general population, we found an elevated anti-HCV prevalence in alcohol-dependent patients (5.2%; 95% confidence interval, 3.2%-7.2%), whereas anti-Hbc immunoglobulin G prevalence (8.3%; 95% confidence interval, 5.7%-10.8%) corresponded to normal rates. Liver enzyme levels significantly differed between patients with chronic, past/remitted, or no HCV infection. On an observational level, a history of injection drug use or nonprofessional tattooing emerged as potential risk factors. In 1 of 10 patients, antiviral therapy was initiated. This 1 patient achieved the end-of-treatment response after extended rapid virological response, despite continuous alcohol consumption.CONCLUSIONS: The elevated HCV infection rates in our sample and the higher levels of fibrosis biomarkers in those with positive polymerase chain reaction corroborate previous findings and emphasize the importance of HCV screening in this population, particularly if further risk factors like injection drug use are given. Factors influencing treatment reluctance and conditions that may enhance the feasibility of antiviral treatment in alcohol-dependent patients should be subject of further research.",
keywords = "Adult, Alcoholism, Antiviral Agents, Biological Markers, Female, Germany, Hepacivirus, Hepatitis B, Hepatitis B virus, Hepatitis C, Humans, Liver Function Tests, Male, Mass Screening, Medication Adherence, Middle Aged, Prevalence, Risk Factors, Serologic Tests",
author = "Schmidt, {Christiane Sybille} and Daniela Sch{\"o}n and Bernd Schulte and Stefan L{\"u}th and Susanne Polywka and Jens Reimer",
year = "2013",
doi = "10.1097/ADM.0b013e3182a50817",
language = "English",
volume = "7",
pages = "417--21",
journal = "J ADDICT MED",
issn = "1932-0620",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

RIS

TY - JOUR

T1 - Viral hepatitis in alcohol-dependent inpatients: prevalence, risk factors, and treatment uptake

AU - Schmidt, Christiane Sybille

AU - Schön, Daniela

AU - Schulte, Bernd

AU - Lüth, Stefan

AU - Polywka, Susanne

AU - Reimer, Jens

PY - 2013

Y1 - 2013

N2 - OBJECTIVES: Most epidemiological literature on the prevalence of viral hepatitis in alcohol-dependent patients is based on older data. This study aimed to provide current estimates and an assessment of risk factors. We further investigated whether the initiation of antiviral hepatitis C virus (HCV) treatment is feasible after detoxification.METHODS: We assessed serological markers for hepatitis B virus (HBV) and HCV infection and liver enzyme levels (alanine aminotransferase, aspartate aminotransferase, γ-glutamyltransferase) in a sample of 463 inpatients in a tertiary care hospital, fulfilling International Classification of Diseases, Tenth Revision criteria for alcohol dependence. A subsample of 141 patients was interviewed on addiction history and risk factors for HCV acquisition. All patients with an indication for antiviral treatment were followed up.RESULTS: Compared with that in the general population, we found an elevated anti-HCV prevalence in alcohol-dependent patients (5.2%; 95% confidence interval, 3.2%-7.2%), whereas anti-Hbc immunoglobulin G prevalence (8.3%; 95% confidence interval, 5.7%-10.8%) corresponded to normal rates. Liver enzyme levels significantly differed between patients with chronic, past/remitted, or no HCV infection. On an observational level, a history of injection drug use or nonprofessional tattooing emerged as potential risk factors. In 1 of 10 patients, antiviral therapy was initiated. This 1 patient achieved the end-of-treatment response after extended rapid virological response, despite continuous alcohol consumption.CONCLUSIONS: The elevated HCV infection rates in our sample and the higher levels of fibrosis biomarkers in those with positive polymerase chain reaction corroborate previous findings and emphasize the importance of HCV screening in this population, particularly if further risk factors like injection drug use are given. Factors influencing treatment reluctance and conditions that may enhance the feasibility of antiviral treatment in alcohol-dependent patients should be subject of further research.

AB - OBJECTIVES: Most epidemiological literature on the prevalence of viral hepatitis in alcohol-dependent patients is based on older data. This study aimed to provide current estimates and an assessment of risk factors. We further investigated whether the initiation of antiviral hepatitis C virus (HCV) treatment is feasible after detoxification.METHODS: We assessed serological markers for hepatitis B virus (HBV) and HCV infection and liver enzyme levels (alanine aminotransferase, aspartate aminotransferase, γ-glutamyltransferase) in a sample of 463 inpatients in a tertiary care hospital, fulfilling International Classification of Diseases, Tenth Revision criteria for alcohol dependence. A subsample of 141 patients was interviewed on addiction history and risk factors for HCV acquisition. All patients with an indication for antiviral treatment were followed up.RESULTS: Compared with that in the general population, we found an elevated anti-HCV prevalence in alcohol-dependent patients (5.2%; 95% confidence interval, 3.2%-7.2%), whereas anti-Hbc immunoglobulin G prevalence (8.3%; 95% confidence interval, 5.7%-10.8%) corresponded to normal rates. Liver enzyme levels significantly differed between patients with chronic, past/remitted, or no HCV infection. On an observational level, a history of injection drug use or nonprofessional tattooing emerged as potential risk factors. In 1 of 10 patients, antiviral therapy was initiated. This 1 patient achieved the end-of-treatment response after extended rapid virological response, despite continuous alcohol consumption.CONCLUSIONS: The elevated HCV infection rates in our sample and the higher levels of fibrosis biomarkers in those with positive polymerase chain reaction corroborate previous findings and emphasize the importance of HCV screening in this population, particularly if further risk factors like injection drug use are given. Factors influencing treatment reluctance and conditions that may enhance the feasibility of antiviral treatment in alcohol-dependent patients should be subject of further research.

KW - Adult

KW - Alcoholism

KW - Antiviral Agents

KW - Biological Markers

KW - Female

KW - Germany

KW - Hepacivirus

KW - Hepatitis B

KW - Hepatitis B virus

KW - Hepatitis C

KW - Humans

KW - Liver Function Tests

KW - Male

KW - Mass Screening

KW - Medication Adherence

KW - Middle Aged

KW - Prevalence

KW - Risk Factors

KW - Serologic Tests

U2 - 10.1097/ADM.0b013e3182a50817

DO - 10.1097/ADM.0b013e3182a50817

M3 - SCORING: Journal article

C2 - 24189174

VL - 7

SP - 417

EP - 421

JO - J ADDICT MED

JF - J ADDICT MED

SN - 1932-0620

IS - 6

ER -